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operators. Inadvertent underheparinization in these two
groups has been proposed as a possible explanation by
Smith and associates,4 because the diatomaceous earth
(Celite)–based ACT used in these two series is spuriously
raised in the presence of aprotinin. Westaby and cowork-
ers3 point out that this vital information was not available
when aprotinin (Trasylol) was released into the market-
place.
Goldstein and colleagues5 recently reported their expe-
rience with aprotinin use in this specific group of patients;
they found no differences from a historical case-matched
control group in operative mortality and perioperative
myocardial infarction rates. Renal dysfunction was more
common in the aprotinin group (29.2% vs 8.3%), but not
significantly so (no p value was given). In the series of
Goldstein and colleagues,5 kaolin-based ACT (aprotinin
does not affect this measurement) was kept above 500
seconds and Celite-based ACT was maintained above 750
seconds. Their conclusions are totally at odds with those
of Sundt and coworkers2 and Westaby and colleagues.3
In our case, kaolin-based ACT was used and kept within
accepted guidelines. It is noteworthy that the St. Louis
group encountered a similar case of acute right ventricular
failure from pulmonary thrombosis or embolism. This
case is the only other such complication ever reported
with this type of operation. In this case, no evidence of
preoperative venous thrombosis was present at autopsy.
We firmly believe that this patient was not underhepa-
rinized.
Is aprotinin safe? We concur with Westaby and cowork-
ers3 in saying that we do not know. Only a prospective
randomized trial will yield the answer. Does it actually
produce a benefit? In the series of Goldstein and col-
leagues,5 there was no benefit in terms of total transfusion
requirements. Unless aprotinin results in significantly
fewer patients needing blood transfusions and fewer
transfusions per patient, differences in volume of drainage
and number or type of blood products used are relatively
unimportant.
This case strongly implicates aprotinin use in intravas-
cular thrombosis; acute pulmonary thrombosis in this
setting is extremely rare. This patient was not underhepa-
rinized, nor had she any known coagulation diathesis. Is
this so surprising? Put simply, we do not know what
aprotinin’s physiologic role is, how it works, or how much
to give—or even when the best time to give it is. What we
do know is that it sure does work; is it surprising when it
works too well? To quote Voltaire, “We use drugs about
which we know very little in patients in whom we know
even less.”
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CONCENTRIC LEFT VENTRICULAR HYPERTROPHY LATE AFTER AORTIC VALVE REPLACEMENT
IN TAKAYASU’S ARTERITIS
Yasushi Terada, MD,a Toshio Mitsui, MD,a Yasuhiko Wanibuchi, MD,b Ikutarou Kigawa, MD,b
Sachito Fukuda, MD,b Tomoaki Jikuya, MD,a and Kenji Okamura, MD,a Tsukuba and Tokyo, Japan
The clinical features of aortic regurgitation in Takaya-
su’s arteritis differ from those in other rheumatic or
degenerative valve diseases. In addition to the inflamma-
tory vascular lesions, ventricular arrhythmias occur more
often, and concentric left ventricular hypertrophy occurs
even in the presence of aortic regurgitation.1 The geom-
etry of the left ventricle after aortic valve replacement
(AVR) for Takayasu’s arteritis is unknown and was the
focus of this study.
Patients and methods. Until 1997, 10 female and three
male patients aged 34 to 68 years (mean age 49 years)
underwent AVR for aortic regurgitation in Takayasu’s
arteritis. There were multiple vascular lesions. AVR was
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performed in 10 patients, aortic root reconstruction was
performed in one, AVR plus graft replacement of the
dilated ascending aorta was performed in one, and AVR
plus mitral valve replacement was performed in one. The
prostheses used included four 27 mm, six 25 mm, and
three 23 mm mechanical valves. No vascular reconstruc-
tion was done simultaneously. There was one in-hospital
death, and one patient died of pneumonia 2 months after
the operation. The remaining 11 patients were included in
the study.
Standard M-mode and two-dimensional echocardio-
grams and color Doppler echocardiograms were obtained
a mean of 50.6 months after AVR (range 2 to 180
months). Left ventricular mass was calculated by the
American Society of Echocardiography cube method.
Concentric hypertrophic ratio (CHR) was calculated as
follows2:
CHR 5 WT/~LVEDD 1 WT!
where WT is wall thickness (interventricular septal thick-
ness plus left ventricular posterior wall thickness) and
LVEDD is left ventricular end-diastolic dimension.
Results. A small peri–prosthetic valve leakage was seen
in one patient. There was a significant reduction in left
ventricular dimensions (p , 0.01) and left ventricular
mass index (p , 0.01) after the operation. The left
ventricular wall thickened (p , 0.05) and the CHR
increased (p , 0.01) significantly after the operation
(Table I, Fig. 1).
Discussion. Good recovery of the clinical condition and
cardiac function after AVR has been reported for patients
with Takayasu’s arteritis.3 Our study showed an increase
in the left ventricular wall thickness despite decreased
ventricular dimensions at 50.6 months’ mean follow-up.
Our patients showed a 40% regression of left ventricu-
lar mass after AVR, which may be a result of the left
ventricular volume unloading. AVR was accompanied by
at least partial regression of left ventricular hypertrophy.4
About 20% to 40% left ventricular mass reductions are
reported in the literature for mean follow-up times rang-
ing from 1 month to 1 year.
Despite left ventricular mass regression, the left ventri-
cle exhibited concentric hypertrophy. The mechanism is
unclear; however, we speculate that long-standing pres-
sure overload may account for this geometric change.
Preoperative catheterization revealed the pressure in the
ascending aorta to be 160.1 6 27.7 mm Hg (range 120 to
210 mm Hg). The value of peripheral blood pressure is
incorrect, because the aorta and its branches are affected
by an inflammatory process in some patients. We have no
data to support this conjecture, but inflammatorily thick-
ened aorta may produce a low wall elasticity and decrease
the Windkessel effect, resulting in high systolic pressure at
the aortic root. Control of the inflammation was poor in
nine of 11 patients after the operation, although five of
those patients had received prednisolone. Improvement
of stenosed arteries and a decrease in the thickening of
the arterial wall5 during corticosteroid therapy have been
reported. Control of hypertension and inflammation may
be necessary to obtain good long-term results.
In summary, AVR released the left ventricle from
volume overload in patients with Takayasu’s arteritis.
However, concentric left ventricular hypertrophy occurred
at 50.6 months’ mean follow-up.
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Table I. Preoperative and postoperative parameters
Preoperative
measurements
Postoperative
measurements
p
Value
LVEDD (mm) 64.7 6 11.6 45.0 6 8.2 p , 0.01
LV end-systolic
dimension (mm)
44.8 6 10.8 31.2 6 11.4 p , 0.01
LV fractional
shortening (%)
31.6 6 6.5 31.8 6 14.2 NS
LVWT (mm) 22.4 6 3.8 25.8 6 2.2 p , 0.05
LV mass index
(gm/m2)
229.8 6 32.5 136.4 6 24.5 p , 0.01
CHR 0.28 6 0.07 0.37 6 0.05 p , 0.01
LV, Left ventricular, WT, wall thickness; NS, not significant.
Fig. 1. Left ventricular wall thickness after operation.
Time after the operation is presented as the logarithm of
time (in months).
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